ARTICLES BY LOUIS

• Outsourcing Growth, And The Cold (Storage Monitoring) Truth

  8/17/2026

  Chief Editor Louis Garguilo superimposes two reports: one on a precise subject, cold chain monitoring; the second an analysis of the entire contract manufacturing market.  What brings the two together? "Growth, its various components, and interpretations." The cold chain monitoring report is prime example of the components of growth demonstrated in the overall biopharma outsourcing market report.

• Lower Court Agrees With WuXi AppTec (And Many Of Us)

  8/14/2026

  A lower-court ruling does not make a victory. But it adds a little sanity to this melodrama. On August 7, a U.S. District Judge did something that has been surprisingly rare in the long-running WuXi AppTec/BIOSECURE Act saga: He looked at the U.S. government's case for labeling WuXi a “Chinese military company” and decided the government had not shown enough evidence. Analysis from Chief Editor Louis Garguilo.

• Mission-Driven Professionals And Students Build America's Supply Chains

  8/10/2026

  Tales of purpose-led careers that bring innovations to business leaders and opportunities to university students. They inspire us. Chief Editor Louis Garguilo documents two such professionals who have combined to help domestic manufacturing organizations locate each other and power their operations, and to get students involved in the industry.

• Global Ties, Good Fortune Bind Biotech And CDMO

  8/3/2026

  Asset development and outsourcing strategies can be intriguing, and full of global connections. Those attributes surface immediately in a conversation with Hyung Heon Kim, Chief Executive Officer and President, MetaVia, a Cambridge, Mass.-based biotech. The company reformed recently, but has roots back to 90 years of South Korean pharma history. Tracing the CDMO relationship MetaVia has is also part of the organization’s history. “Ours is a fun journey to tell,” says Kim. Fun, informative, and enlightening.

• Are Drug Sponsors Reshaping Today's CDMOs?

  7/27/2026

  CDMO mergers and acquisitions and the addition of services has been a dominating trend in outsourcing; comprehensive offerings and scale are proclaimed indispensable to customers. Sufficient time has now elapsed so we can evaluate this era of more and those claims.  Chief Editor Louis Garguilo looks into the evidence, and comes up with some interesting developments.

• The Curious Route Back To The In-Person Conference

  7/23/2026

  We've acquired one of the industry's fastest-growing outsourcing conference franchises. We’re back in the live events business; that's great news. This new partnership also sets us to wondering: As an outsourcing industry, where in fact are we regarding in-person and virtual events? I asked my new colleagues, the co-founders of PharmaSource and CDMO Live conferences, Luke Bilton and Chris Kilbee.

• Velocity The Key Metric For External Manufacturing

  7/20/2026

  What separates high-performing sponsor-CDMO partnerships from struggling ones? Velocity. With 30+ years of experience, Ratna Shekhar is focused on how real speed drives results. Chief Editor Louis Garguilo investigates.

• Fundamentals Over Factors: How To Select Your CDMO

  7/16/2026

  Chief Editor Louis Garguilo is concerned about how drug sponsors evaluate external partners. "Beware the selection of CDMOs for factors over fundamentals," he writes in his latest editorial. This injunction warns against getting entangled in a spreadsheet of details when choosing a CDMO. It’s a difficult task. We continue to add factors we deem as crucial to the selection process, and thus have arrived at the point where we actually talk ourselves out of opting for the best CDMO for our needs.

• South Korea's Turn: CDMO Powerhouse Adds Biotech Innovation

  7/13/2026

  Where CDMOs first flourish, and clinical trials pick up, biotech innovation follows. It has been the China model, and now the addition of biotechs and biotech investment from within and without has South Korea as the new attention-grabbing nation participating throughout our industry. Here's an in-depth analysis from Chief Editor Louis Garguilo.

• A Vaccine To Prevent Breast Cancer Recalibrates The Possible

  7/8/2026

  A few times in life you hear something that precipitates a pause – a reality recalibration. Like experienced by Amit Kumar, chairman and CEO, Anixa Biosciences, when he came upon a technology he thought could enable a prophylactic vaccine to prevent breast cancer – perhaps eliminate the disease like we've done for polio. He personally invested over $2.5 million, and his development/commercialization strategy is all-outsourcing all the way.